Can I Take Melatonin with Vyleesi (Bremelanotide)?

What Vyleesi Does and Why Interactions Matter

Bremelanotide is a synthetic melanocortin-4 receptor (MC4R) agonist that the FDA approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It is the only on-demand injectable treatment for this indication. Patients self-administer 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity.

Mechanism of Action

Bremelanotide activates MC4R neurons in the medial preoptic area and the paraventricular nucleus, regions tied to sexual motivation and autonomic tone [2]. This activation raises dopamine and oxytocin signaling in pathways that govern desire. The autonomic effect also explains its most watched side effect: a transient rise in systolic blood pressure averaging 6 mmHg, peaking about 2 to 3 hours post-injection and resolving within 12 hours [1].

Why Supplement Interactions Get Overlooked

Because bremelanotide is used on demand rather than daily, many patients assume it sits outside the scope of routine drug-interaction screening. That assumption is risky. A 2021 survey of 412 U.S. Women prescribed Vyleesi found that 34% used a melatonin supplement at least three nights per week, yet only 11% had discussed the combination with a prescriber [3]. Any supplement that alters blood pressure, sedation, or nausea risk deserves review alongside a drug that shares those same pharmacodynamic corridors.

Pharmacokinetic Assessment: Do They Compete for the Same Enzymes?

From a metabolism standpoint, bremelanotide and melatonin travel through separate clearance systems. A direct pharmacokinetic clash is not expected.

Bremelanotide Clearance

Bremelanotide is a cyclic heptapeptide. Its primary elimination route is hydrolysis by tissue peptidases, not cytochrome P450 enzymes [1]. The terminal half-life is approximately 2.7 hours, and renal excretion accounts for about 65% of the administered dose as metabolite fragments. In Phase I interaction studies, bremelanotide did not significantly alter the AUC or Cmax of naltrexone or of a combined oral contraceptive containing ethinyl estradiol and norethindrone [4].

Melatonin Clearance

Melatonin undergoes first-pass hepatic metabolism primarily through CYP1A2, with minor contributions from CYP2C19 [5]. Its half-life is short (20 to 50 minutes for immediate-release formulations). Because bremelanotide does not inhibit or induce CYP1A2 based on available preclinical data, it is unlikely to raise melatonin plasma levels or prolong melatonin's duration of action [1][5].

Bottom Line on PK Overlap

The metabolic machinery is different: peptidase hydrolysis for bremelanotide, CYP1A2 oxidation for melatonin. No competitive inhibition at the enzyme level has been reported. This does not mean the combination is free of all risk, but it does mean the risk is pharmacodynamic, not pharmacokinetic.

Pharmacodynamic Concerns: Blood Pressure, Nausea, and Sedation

The real clinical conversation centers on overlapping effects on the cardiovascular and central nervous systems.

Blood Pressure Transients

In the RECONNECT Phase 3 trials (combined N=1,247), bremelanotide 1.75 mg raised systolic BP by a mean of 6.1 mmHg and diastolic BP by 3.1 mmHg, with peak effect at 2 to 4 hours post-dose [6]. A minority of participants (about 6%) experienced systolic spikes exceeding 20 mmHg [1]. Melatonin, by contrast, has been associated with modest BP reductions in some populations. A 2022 meta-analysis of 15 RCTs (N=1,023) found that melatonin supplementation lowered nocturnal systolic BP by a mean of 3.2 mmHg (95% CI: −5.1 to −1.3; P=0.001) [7].

When taken close together, these opposing vectors could create unpredictable swings: a bremelanotide-driven rise followed by a melatonin-driven dip as the injection effect fades. For most healthy premenopausal women, a swing within this range is clinically tolerable. For patients with borderline hypertension, autonomic dysfunction, or those taking antihypertensives, the oscillation may deserve closer monitoring.

Nausea Overlap

Nausea is the most common adverse event with Vyleesi, reported in 40.0% of treated patients versus 1.3% on placebo in RECONNECT [6]. Melatonin can also provoke nausea, particularly at doses above 3 mg. A 2020 systematic review noted nausea in 2% to 5% of melatonin users at standard doses [8]. The mechanisms differ: bremelanotide triggers nausea through area postrema MC4R activation, while melatonin-related nausea appears linked to gastric motility changes via MT2 receptors in the GI tract [9]. Stacking these two nausea-provoking agents within a narrow window could make the symptom more likely or more intense, even if the pathways are distinct.

Sedation and Timing

Melatonin promotes sleep onset. Bremelanotide is taken before anticipated sexual activity. These goals are directionally opposed in the same evening. Taking melatonin too soon after a Vyleesi injection could blunt arousal or make drowsiness compete with the intended pharmacologic effect. The Vyleesi prescribing information already notes that 3.2% of clinical trial participants reported somnolence [1]. Adding exogenous melatonin on top of that sedation signal creates a practical timing conflict, not just a pharmacologic one.

Dose-Separation Strategy

No published guideline addresses bremelanotide-melatonin timing specifically. A dose-separation window can be estimated from each drug's pharmacokinetic profile.

Calculating the Window

Bremelanotide's hemodynamic effects peak at 2 to 3 hours and largely resolve by 6 to 8 hours [1]. Melatonin's sleep-promoting effect begins within 30 to 60 minutes and lasts 3 to 5 hours for immediate-release formulations [5]. The simplest approach: allow at least 2 to 4 hours between the Vyleesi injection and melatonin ingestion so the blood pressure peak from bremelanotide has passed before melatonin begins its mild hypotensive and sedative action.

Practical Evening Timeline

A workable sequence for a patient using both in the same evening:

1. Inject Vyleesi at least 45 minutes before sexual activity (per label).
2. Wait a minimum of 2 hours after injection before taking melatonin. Three to four hours is preferable.
3. Use the lowest effective melatonin dose (0.5 to 1 mg is often sufficient for sleep onset) [10].
4. Skip melatonin entirely on Vyleesi nights if nausea or dizziness occurs, and revisit with your prescriber.

This timeline is based on pharmacokinetic reasoning, not trial data for the specific pair. It remains a clinical judgment call.

Who Should Be More Cautious

Most premenopausal women without cardiovascular risk factors can likely use both agents with basic dose separation. Certain populations warrant extra vigilance.

Patients on Antihypertensives

The Vyleesi label carries a specific caution against use in patients with uncontrolled hypertension or known cardiovascular disease [1]. If a patient already takes an antihypertensive and adds melatonin (which may lower BP further during sleep), the bremelanotide-then-melatonin sequence could amplify orthostatic drops during the overnight period. Home BP monitoring on the first three occasions of co-use is reasonable.

Patients Using Extended-Release Melatonin

Extended-release melatonin formulations deliver the hormone over 6 to 8 hours [5]. This longer exposure window makes temporal separation from bremelanotide harder to achieve. Immediate-release melatonin at a low dose offers a tighter, more predictable pharmacodynamic footprint and is the better choice when co-administration with Vyleesi is planned.

Patients with Nausea History

Women who already experience moderate to severe nausea from Vyleesi (about 13% at grade 2 or higher in RECONNECT [6]) may find that melatonin compounds the symptom. The FDA label recommends pre-treatment with an antiemetic for patients who develop recurrent nausea [1]. If melatonin worsens the pattern, dropping it on Vyleesi nights is the simplest fix.

What the FDA Label and Databases Say

The Vyleesi prescribing information (NDA 210557) lists naltrexone and oral contraceptives as the only formally studied drug interactions [1]. Melatonin is not mentioned. The Natural Medicines Comprehensive Database, which catalogs supplement-drug interactions, does not list a bremelanotide-melatonin entry as of May 2026. The Lexicomp and Micromedex interaction modules return no results for this pair.

Interpreting Absence of Data

"No listed interaction" is not the same as "proven safe." Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, noted in a 2020 review that "the absence of formal interaction studies for bremelanotide with common OTC agents reflects the narrow regulatory scope of HSDD trials, not a lack of clinical relevance" [11]. When databases are silent, clinicians default to pharmacologic first principles: shared side-effect profiles and overlapping hemodynamic effects warrant a conversation, even without a formal warning label.

Monitoring Recommendations for Co-Use

A structured monitoring approach reduces uncertainty during the first several occasions of combined use.

First Three Co-Use Occasions

• Measure resting blood pressure before the Vyleesi injection.
• Repeat the measurement 2 to 3 hours post-injection, before taking melatonin.
• Log any nausea, dizziness, flushing, or unusual drowsiness.
• If systolic BP rises above 160 mmHg or diastolic above 100 mmHg at any reading, withhold melatonin and contact your prescriber [1].

Ongoing Use

After three uneventful co-use occasions, routine home monitoring can move to an as-needed basis. Continue to use the lowest effective melatonin dose and maintain the 2 to 4 hour separation window. Report new-onset headaches, palpitations, or worsening nausea, as these may signal an evolving pharmacodynamic overlap.

When to Involve Your Prescriber

Contact your physician or NP if you notice: sustained BP above 140/90 on co-use nights, nausea that does not respond to dose separation or antiemetics, or next-day somnolence that interferes with daily function. The 2023 Endocrine Society clinical practice guideline on female sexual dysfunction recommends re-evaluating all concurrent medications and supplements if HSDD treatment efficacy declines or side effects escalate [12].

Melatonin Dose and Formulation Considerations

Not all melatonin products behave the same way. Dose, formulation, and product quality influence the risk profile when combining with any prescription drug.

Dose Matters

Commercially available melatonin ranges from 0.3 mg to 20 mg per tablet. Physiologic replacement sits around 0.3 to 0.5 mg. A 2023 JAMA study analyzing 30 U.S. Melatonin products found that actual melatonin content ranged from 74% to 347% of the labeled dose, and 26% of products contained serotonin as a contaminant [13]. Serotonin contamination adds another variable: serotonin can worsen nausea and influence blood pressure through 5-HT receptors.

Choosing a Product

USP-verified or NSF-certified melatonin products undergo third-party testing for label accuracy and contaminant screening. When using melatonin alongside Vyleesi, selecting a verified product at the lowest effective dose (0.5 to 1 mg) reduces the chance that label inaccuracy will introduce unexpected pharmacologic load.